The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...
The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...
Bet your bottom dollar, at least one little redheaded girl will be longing for brighter days in Virginia Beach this weekend. And warmer days after this week’s heavy snow will have a lot of people ...
Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...
BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
“Educating people about the signs and symptoms of MCT8 deficiency, as well as the journey of patients like my son Colton is critically important,” added Favre. “On Rare Disease Day and every day, MCT8 ...
Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic ...
Zacks Small Cap Research on MSN1d
NRXBF Pushing into US Market
NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting ...
Cardiol Therapeutics' CardiolRx shows promise in treating heart conditions. Click here to read more about CRDL stock and why ...
Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe ...